Deschatelets Pascal 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 21, 2025
Insider Transaction Report
Form 4
Deschatelets Pascal
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-01-17$29.96/sh−750$22,469→ 1,137,445 total - Award
Common Stock
2025-01-21+15,045→ 1,152,490 total
Footnotes (2)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
- [F2]This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service.